Alfresa Group

Corporate Profile 2024–2025

Message from the President

The Alfresa Group’s Aspiration(Long-Term Goals)

We create and deliver

The Alfresa Group’s Principles

a fresh life for all.

Our Vision

Our Philosophy

Our Promises

The Alfresa Group’s Basic Sustainability Policy

One important principle of the Alfresa Group is expressed in Our Philosophy, which is to create and deliver a

Environment

fresh life for all. We strive to realize a sustainable society as a corporate group that has taken on the role in thesocial infrastructure of delivering medicines in a reliable, safe, and sincere manner.
The business environment around the Alfresa Group is seeing drastic changes due to factors such as theEnvironmental Policy
Human Rights Policy

Socialsuper-aged society, a shrinking workforce, the rising cost of social security, technological innovation and digita-

Diversity Policy
Procurement Policy

lization, and the evolution of the Community-Based Integrated Care System across Japan.
Against this backdrop, we announced the Alfresa Group’s Medium- to Long-Term Vision in May 2023.
The vision centers on our business strategy and financial and capital strategies and outlines the direction ofImportant
Sustainability Issues
1 Improvement of quality of products and services
2 Value creation and innovation
3 Environmental protection
4 Contribution to local communities
5 Active participation of human resources

GovernanceCompliance Guidelines
Corporate Governance Guidelines

the measures we are undertaking to increase corporate value through fiscal 2032. In addition, we are now in

6 Compliance
7 Risk management
8 Corporate governancethe final fiscal year of our efforts to reach the targets of 22–24 Mid-term Management Plan: Leap into the
Future “An Evolving Healthcare Consortium.”
By strengthening our core businesses in the health and medical fields, cultivating growth businesses, anddeveloping new businesses, we will reinforce and expand our total supply chain services while striving tocreate social value and enhance corporate value by extending healthy life expectancy, contributing to commu-

The Alfresa Group’s Aspiration (Long-Term Goals)

nity healthcare, and promoting innovations in healthcare.

Become a Healthcare Consortium that provides products and services in every health-related field

Ryuji Arakawa
Representative Director & President
Alfresa Holdings Corporation

Medium- to Long-Term Vision
Improve corporate value over the medium to long term by becoming a Healthcare Consortium andimproving capital efficiency through balance sheet controls

The Alfresa Group’s Principles
2 2 – 2 4Management Plan
22–24 Mid-term

Our Philosophy
We create and deliver a fresh life for all.

Leap into the Future

Our Vision
We aim to become a Healthcare Consortium that provides products and services in every health-related field.
Our Promises

Reliability

Safety• We always provide reliable products and services
and strive to enhance customer satisfaction.
• We respect individual characteristics and personalities and strive to maintain and improve a pleasant working environment.
• We raise corporate value as a corporate group
operating in the health-related industry.

Sincerity• We conduct proper trade under fair andfree competition.
• We strive to proactively engage with society byproviding appropriate information in a timely
manner.
• We contribute to local communities through ourbusiness operations.
• We strive to protect the global environment.

“An Evolving Healthcare Consortium”

1. Enhancement of business models and creation of new value
2. Contribution to local health and treatments through united Group efforts
3. Contribution toward a sustainable society through initiatives to protect the environment
4. Promotion of a human resource strategy focused on diversity
5. Cultivation of a corporate culture with compliance as its highest priority
Please see here for more
information on our
Sustainability Policy.

Please see here for more
information on the AlfresaGroup’s Aspiration (Long-Term
Goals).

Please see here formore information on our
Medium- to Long-Term
Vision.

Please see here for more
information on our 22–24
Mid-term Management Plan.

Alfresa Group Corporate Profile 2024–20251

Business Strategy under the Alfresa Group’s Medium- to Long-Term Vision
The Ethical Pharmaceuticals Wholesaling Businessas a Source of Value Creation
The Ethical Pharmaceuticals Wholesaling Business possesses strengths in the form of strong relationships of trust with suppliers, a highly functional logistics infrastructure, and abundant human capital,
which we will utilize to strengthen core businesses, cultivate growth businesses, and develop new businesses. By promoting digitization, digitalization, and digital transformation, we will strengthen andexpand total supply chain services.

Sources of Value Creation

Business Strategy(Strengths of the Ethical Pharmaceuticals
Wholesaling Business)(Enhance and Expand Total Supply Chain
Services)

Creation of Social Value

Strong Relationships of Trust with Suppliers

22–24 Mid-term Management Plan

Leap into the Future “An Evolving Healthcare Consortium”
of business models and1 Enhancement
creation of new value
to local health2 Contribution
and treatments through united Group efforts

Extending Healthy Life Expectancy

The number-one share of sales in Japan
Over 170,000 customer institutions
Approximately 1,680 manufacturers

Highly Functional Logistics Infrastructure
Steady supply system with 220 distribution
bases across Japan• 16 large-scale distribution centers across Japan• Four urban pharmaceuticals centers across Japan• Nine facilities for the management andstorage of regenerative medicine products
across Japan• Two regenerative medicine distribution
stations located in the east and west partsof JapanContributing to Community Healthcare• Workstyle reforms for medical care
professionals• Efficient management of medical institutions• Contribution to the Community-Based
Integrated Care System, etc.

Cultivate Growth Businesses

Healthcare Innovation
Abundant Human CapitalStrengthen Core Businesses• Contributing to domestic and overseas
companies (manufacturers and ventures)
through manufacturing, distribution, andnew services

Approximately 2,800 marketing specialists
Over 2,000 medical management
specialists
Over 2,000 sales assistants

2

Important Sustainability Issue 4

In our pursuit of creating new value, we are working to strengthen and expand our total supply chain services bystrengthening our core businesses, cultivating growth businesses, and developing new businesses.
As part of our contribution to local health and treatments, we are working to provide solutions to health and medical
issues through various digital tools. Examples of such solutions include implementing a system for delivering
pharmaceuticals to patients’ homes that enables all processes—from appointments to medical interviews,
consultations, payments, and delivery procedures—to be completed online, enhancing the operational efficiency of
medical institutions and promoting workstyle reforms for medical practitioners, and developing communication tools toconnect physicians. The Alfresa Group will work as one to meet local healthcare needs and help realize the Community
Health Care Vision.

• Improved access to pharmaceuticals forpatients• Customer health/preventive health• Quality of life improvement

Develop New Businesses

Important Sustainability Issues 1

toward a sustainable society through3 Contribution
initiatives to protect the environment

Important Sustainability Issue 3

Furthering Digital Transformation (DX)(Business reform, information utilization,and business creation)

1

Expansion of and Reforms to the Business Portfolio

22–24 Mid-term Management Plan

New Businesses

Growth businesses

New businesses• Medical goods• Regenerative medicine supply chain(medical devices, diagnostic
reagents, nutritional foods, etc.)• Health technology, data-driven business• Self-prevention products• New channels(Self-Medication Products
Wholesaling Business)

Existing Businesses
GrowthGrowthExisting Businesses

Alfresa Group’s Medium- to Long-Term Vision(Cell Resources Corporation)(GEKKA WORKS Co., Ltd., and coordination between health technology
companies)

New Businesses

Growth businesses(¥850.0 billion)

New businesses(¥150.0 billion)• Medical goods(Medical devices, diagnostic reagents,
nutritional foods, etc.)• Self-prevention (SP) products• New channels(Self-Medication Products Wholesaling
Business)• Consigned manufacturing of• Regenerative medicine supply

chain• Health technology, data-driven

business• Treatment-adjacent business(beauty, animal-related)• Dispensing center business, etc.

pharmaceuticals(Formulations with high pharmacological activity)• Newly developed

pharmaceuticals• Post-marketing surveillance, etc.

• Ethical Pharmaceuticals Wholesaling Business (23.4% of
the Japanese market)• Self-Medication Products Wholesaling Business• Manufacturing Business• Dispensing Pharmacy Business

Fiscal 2023 (actual results)
Net Sales
Operating Income
ROE

2Core businesses (¥3.0 trillion)¥2.858 trillion¥38.4 billion
6.1%

Alfresa Group Corporate Profile 2024–2025

Enhancement

Enhancement

Core businesses• Ethical Pharmaceuticals• Self-Medication Products
Wholesaling Business
Wholesaling Business(27.5% of the Japanese market) • Manufacturing Business
Expand share of territory and• Dispensing Pharmacy Businesssuppliers
Expand specialty pharmaceuticals
Streamline delivery, implement
DX, etc.

Enhance and Expand Total Supply Chain Services

2

Advance resource recycling

3

Promote the prevention ofenvironmental pollution and coexistence with living organisms

In line with the Alfresa Group’s Environmental Policy, we are focusing on efforts to become carbon neutral, advanceresource recycling, and promote coexistence with living organisms. Through our environmentally friendly businessactivities, we aim to help realize a sustainable society.

In an effort to create value, we will expand and reform our business portfolio by enhancing and expanding our total supply chain services.
Expansion of and Reforms to the Business Portfolio (Net Sales)

Promote efforts tobecome carbon neutral

4

Willingness

Promotion of a human resource
strategy focused on diversity

Important Sustainability Issue 5

In accordance with the Alfresa Group’s Diversity Policy, we are pursuing initiatives
to create a group of strong individuals who embrace diversity, make full use of
their individuality and talents, and work together with diverse colleagues to achieve
their goals.

of a corporate culture
5 Cultivation
with compliance as its highest priority

Abilityto adapt

to venture into
unchartedareas

to changing
environments

High
ethicalstandards

that earn trust

Strongexpertiseneeded forsustainablegrowthStrongsense ofmissionfor work that
supports life

Important Sustainability Issue 6

The Alfresa Group takes past violations of the Antimonopoly Act very seriously and has repeatedly implemented a
PDCA cycle to prevent recurrence.

Fiscal 2032 (target results)¥4.0 trillion¥70.0 billion or higher
8.0% or higher

Alfresa Group Corporate Profile 2024–2025

3

Our Businesses

The Alfresa Group’s main businesses are the Ethical Pharmaceuticals Wholesaling Business, the SelfMedication Products Wholesaling Business, the Manufacturing Business, and the Medical-Related
Business. We are striving for the realization of a Healthcare Consortium to contribute to people’s health.
Ethical Pharmaceuticals Wholesaling Business

Self-Medication Products Wholesaling Business

Manufacturing Business

Medical-Related Business

Focusing on ethical pharmaceuticals, we deliver a wide rangeof products— including diagnostic reagents, medical devices
and materials, and nutritional foods— from our distribution
centers— which are located across Japan and are capable ofaccurately handling a high throughput— to hospitals, clinics,
and dispensing pharmacies. In addition, our expert sales
force provides support to our customers. We are contributing
to the health of community members by meeting theirhealthcare needs.

The Self-Medication Products Wholesaling Business focuseson over-the-counter drugs and delivers them, as well as
health foods, supplements, and other products, to drugstoresand pharmacies. We meet customer needs as a Total
Healthcare Merchandising Wholesaler (THMW), offering a fullproduct lineup, a reliable product supply system, and highvalue-added marketing activities that help customers withquestions such as how to create optimal storefronts.

From a comprehensive perspective encompassing prevention, diagnosis, and treatment, we manufacture and market
high-quality active pharmaceutical ingredients (APIs), pharmaceuticals, diagnostic reagents, and medical devices that meet
GMP*1 and QMS*2 requirements. We research, develop,
manufacture, and market unique and distinctive products,
and undertake contract manufacturing of pharmaceuticals.

In an active effort to expand its business areas, the AlfresaGroup is working to meet a variety of medical needs throughits dispensing pharmacy business and other medical-related
businesses. Our dispensing pharmacy business pursues
further added value as a community-based pharmacy.

Net Sales Composition
by Product Field

Net Sales Composition by Medical
Product Category

Net Sales Composition
by Product Field

Net Sales Composition
by Sales Channel*1 GMP (good manufacturing practice): standards for manufacturing control andquality control of pharmaceuticals and quasi-drugs*2 QMS (quality management system): standards for manufacturing control andquality control of medical devices and external diagnostic reagents

Net Sales Composition by Product Field

Community event:“Children’s pharmacy”

Ethical pharmaceuticals 88.4%
Diagnostic reagents
4.0%
Medical devices/equipment 5.4%
Others2.2%

Products with drug creation
premiums
Patented drugs, etc.
Long-listed drugs
Generic drugs

38.9%
37.9%
11.3%
11.9%

OTC pharmaceuticals
Supplements andhealth foods, etc.
Others56.4%

Drugstores
81.8%
Pharmacies
1.1%
General merchandise stores 5.2%
Others
11.9%

21.4%
22.2%

Ethical pharmaceuticals
Diagnostic reagents
Medical devices, etc.

31.3%
7.6%
12.8%

Courteous and kind treatment ofpatients

APIs
13.4%
Consigned manufacturing 31.6%
Others3.3%

Demonstrating Group
Synergies throughCollaboration between
Business Segments
Information provided by marketing
specialists (MSs)*

Product delivery (medical products, etc.)

A selection of our product lineup

Store shelving proposal for optimal
storefronts

Marketing activities by MRs

R&D at Alfresa Pharma Corporation’s
Ibaraki Research Center* Sales personnel within the EthicalPharmaceuticals Wholesaling Business

4

Overseas Business

New Businesses

In addition to the development of the Company, we are expanding business throughalliances with overseas companies, primarily in Asia. In China, the Group established thejoint venture REMEJE PHARMACEUTICALS (CHINA) CO., LTD., in 2005 as a representative office for pharmaceuticals and healthcare-related products. In Vietnam, the Groupestablished the joint venture Alfresa Codupha Healthcare Vietnam Co., Ltd. (Alcopha), to
conduct import and sales, mainly of medical devices and materials and diagnostic
reagents.
We aim to expand our business in the Asian market by enhancing our lineup of
healthcare-related products to serve as a bridge between Japanese companies andoverseas local markets.

We are working to provide solutions to health and medical issues through health technology and other digital tools. Examples of such solutions
include implementing a system for delivering pharmaceuticals to patients’ homes that enables all processes—from appointments to medical
interviews, consultations, payments, and delivery procedures—to be completed online, enhancing the operational efficiency of medical institutions and promoting workstyle reforms for medical practitioners, developing communication tools to connect physicians, and establishing mechanisms that benefit pharmaceutical companies’ medical representatives.
In addition, we are establishing a supply chain for regenerative medicine products, which have seen advances in practical applications inrecent years. Established in 2022, Cell Resources Corporation is building a system for the stable supply of domestic cellular raw materials andthe consigned manufacturing of processed cells and regenerative medicine products to contribute to the industrialization of regenerative medicine. In terms of storage and transportation, the Group has set up two regenerative medicine distribution stations and nine storage facilities forregenerative medicine products, establishing an environment that enables customers to entrust us with distribution. At the sametime, we are continuously working to improve our expertise in transportation and delivery.

Alfresa Group Corporate Profile 2024–2025

Alcopha headquarters

Alfresa Group Corporate Profile 2024–2025

5

The Alfresa Group’s Competitive Advantages

Talent with a Sense of Mission
Number of “our people”*1

The Alfresa Group is engaged in a range of businesses, from the manufacture of APIs and the
manufacture and wholesale of pharmaceuticals and other products to the operation of dispensing pharmacies. With the unified development of these businesses, the Group strives tomeet the full range of medical needs.

15,557*2

MSs(marketing specialists)SAs(sales assistants)

Pharmacists

2,818

2,733

1,226

Over 15,000 of our people are working as one, with a strong sense of mission, to promote the business as
a part of a social infrastructure that must not be interrupted at any time.
*1 The Alfresa Group refers to its employees as “our people.”*2 This figure includes 3,040 part-time and temporary employees (annual average).

Ethical Pharmaceuticals Wholesaling

Business

Self-Medication Products Wholesaling

Business

Manufacturing Business

Five production
bases

Pharmaceuticals
Manufacturers

Handling
approx.

470

Medical-Related Businesskinds

Pharmaceuticals
Wholesalers
We hold the position of Japan’s top wholesaler of ethicalpharmaceuticals and are driven by broad transactions
with pharmaceuticals manufacturers, a robust distribution
platform, and strong relationships of mutual trust withcustomers. Moreover, by leveraging the advantages andassets that come with this top position, we are aiming tocreate new value by taking on the role of connecting medical care, nursing care, municipalities, and other services.

of items

We have four domestic plants in Akita, Gunma, Chiba, andOkayama prefectures as well as one overseas plant in Qingdao,
China. We have a lineup of approximately 470 items, including
pharmaceuticals, diagnostic reagents, medical devices, and APIs.
Our primary areas of expertise are developing and manufacturing pharmaceutical products for central nervous system diseases such as sleep disorders and epilepsy, medical equipment
systems for colorectal cancer screenings, various point-of-care
testing (POCT) reagents for infectious diseases, and medical
equipment such as surgical sutures.

Ethicalpharmaceuticals
wholesaling

No.1

MedicalInstitutions

Retailers

Hospitals, clinics,
nursing carefacilities, etc.

net sales*

Patients* According to the latest edition of Pharmaceuticals
Industry Rankings (Drugmagazine Co., Ltd.)

Dispensing
pharmacies

Nationwide
pharmaceuticals
distribution network

179

220

approx.
distribution bases*

6,453

We are working on launching promotions that utilize
digital technology, acquire self-prevention (SP) products, and boost sales.
We also plan to carry out shelving allocations
categorized according to illness or health concerns
and to propose attractive sales floor layouts to ourcustomers in the drugstore industry.

* Total number of distribution bases for the EthicalPharmaceuticals Wholesaling Business and the
Self-Medication Products Wholesaling Business(including storage facilities and distribution
stations for regenerative medicine)* Those who have accurate knowledge
and understanding of dementia and cansupport dementia patients and theirfamilies in the community

We operate 179 dispensing pharmacies, mainly in the Kanto
and Tohoku regions, stretching from Hokkaido to the Kansai
region. At these stores, we actively communicate with local
communities by providing events such as healthcare consultations and work experience programs for children at pharmacies. Furthermore, around 6,400 dementia supporters
always take care to provide appropriate help in a timely
manner.

We are establishing a distribution system to meet the needs of our customers,
including medical institutions, dispensing pharmacies, and drugstores, byeffectively allocating high-capacity distribution centers through a nationwide
network of branches and offices. In 2024, operations commenced at the Tsukuba
Distribution Center in Ibaraki Prefecture and the Yamaguchi Ube Center inYamaguchi Prefecture under our Ethical Pharmaceuticals Wholesaling Business.

Production

Distribution
Enhancement and expansion of total supply

storesDementia supporters*

Self-Medication
Products Wholesalers

Suppliers

Procurement

Dispensing
pharmacies,
drugstores

Sales
chain services for medical and pharmaceutical products
Note: Figures shown are as of March 31, 2024.

6

Alfresa Group Corporate Profile 2024–2025

Alfresa Group Corporate Profile 2024–2025

7

Alfresa Group Companies

Corporate Overview

As of June 26, 2024

Ethical Pharmaceuticals Wholesaling BusinessCorporate Name: Alfresa Holdings Corporation
Established:

September 29, 2003

Alfresa Corporation

Shikoku Alfresa Corporation

Representative: Yusuke Fukujin, President
Head office: 7, Kanda-Mitoshirocho, Chiyoda-ku, Tokyo
Business domain: Ethical Pharmaceuticals Wholesaling Business

Representative: Yosuke Kiyoshita, President
Head office: 1255-10, Fuke Kou, Kokubunjicho, Takamatsu, Kagawa Prefecture
Business domain: Ethical Pharmaceuticals Wholesaling Business

Paid-in Capital(Consolidated):¥18,454 million

Net Sales(Consolidated):¥2,858,500 million(Fiscal year ended March 31, 2024)

TS Alfresa Corporation

Meisho Co., Ltd.

Representative: Takuji Takahashi, President
Head office: 1-2-19, Shoko Center, Nishi-ku, Hiroshima, Hiroshima Prefecture
Business domain: Ethical Pharmaceuticals Wholesaling Business

Representative: Hiromitsu Kawajiri, President
Head office: Ha 1, Muryoji-machi, Kanazawa, Ishikawa Prefecture
Business domain: Ethical Pharmaceuticals Wholesaling Business

RYUYAKU CO., LTD.

Tohoku Alfresa Corporation

Representative: Katsuya Higa, President
Head office: 5-6-5, Makiminato, Urasoe, Okinawa Prefecture
Business domain: Ethical Pharmaceuticals Wholesaling Business

Representative: Shinya Uchida, President
Head offices: Sendai Headquarters, 4-8-5, Oroshimachi, Wakabayashi-ku, Sendai,
Miyagi Prefecture
Koriyama Headquarters, 1-46-1, Kikutamachi Oroshi, Koriyama,
Fukushima Prefecture
Business domain: Ethical Pharmaceuticals Wholesaling BusinessAlfresa Medical Service Corporation
Representative: Tamotsu Shioda, President
Head office: 2-3-14, Kudan-Minami, Chiyoda-ku, Tokyo
Business domain: SPD business (contract distribution service in hospitals) andwholesaling of medical materials

A·L Plus Co., LTD.
Representative: Masahiko Hagino, President
Head office: 1-12-1 Uchikanda, Chiyoda-ku, Tokyo
Business domain: Pharmaceutical distribution and logistics (warehousing,transportation, delivery) and moving, office relocation, and storage

Address:

1-1-3, Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan

Business:

Managing subsidiaries that deal with wholesaling, manufacturing,marketing, and the import/export of pharmaceuticals, diagnostic
reagents, medical devices/equipment, etc., and operating dispensing pharmacies and conducting related business

Ryuji Arakawa
Representative Director & President
Seiichi Kishida
Representative Director & Executive Vice President
Yusuke Fukujin
Representative Director & Executive Vice President
Shigeki Ohashi
Director, Vice President & Executive Officer
Directors andToshiki Tanaka
Director, Vice President & Executive Officer
Audit &
Hisashi Katsuki
Director
Supervisory
Koichi Shimada Director
Board Members:
Takashi Hara
Director (Outside)
Manabu Kinoshita Director (Outside)
Toshie Takeuchi
Director (Outside)
Kimiko Kunimasa Director (Outside)

Masakazu Ozaki
Yuji Ueda
Yoshitaka Kato
Takashi Ito
Hiroshi Kizaki

Audit & Supervisory Board Member (Standing)
Audit & Supervisory Board Member (Standing)
Audit & Supervisory Board Member (Outside)
Audit & Supervisory Board Member (Outside)
Audit & Supervisory Board Member (Outside)

Alfresa Group Integrated Report

Alfresa Shinohara Chemicals Corporation
Representative: Yuichi Shinohara, President
Head office: 9-41, Minamigoza, Kochi, Kochi Prefecture
Business domain: Wholesaling business of diagnostic reagents, research
reagents, nursing care equipment, and analytical equipment forlaboratories, etc.

https://www.alfresa.com/eng/ir/library/annual_report/

Specialty Medical Distribution Corporation
Representative: Yasuhide Sawado, President
Head office: 7 Kanda-Mitoshirocho, Chiyoda-ku, Tokyo
Business domain: Distribution of specialty pharmaceuticals, etc.

Corporate Website
Home Page

Self-Medication Products Wholesaling Business

https://www.alfresa.com/eng/

Sustainability

https://alfresa.com/eng/csr/

Alfresa Healthcare Corporation
Representative: Makoto Nishida, President
Head office: 3-11-5, Nihonbashi-Honcho, Chuo-ku, Tokyo
Business domain: Self-Medication Products Wholesaling Business

Manufacturing BusinessAlfresa Pharma Corporation

QINGDAO NESCO MEDICAL CO., LTD.

Representative: Koichi Shimada, President and CEO
Head office: 2-2-9, Koku-machi, Chuo-ku, Osaka, Osaka Prefecture
Business domain: Manufacturing, import/export, and marketing of pharmaceuticals, diagnostic reagents, medical devices, and materials forpharmaceuticals, etc.

Representative: Yoshikazu Oe, Chairman
Head office: No. 11 Xinghai Rd., Chengyang, Qingdao, Shandong, China
Business domain: Manufacturing, export, and sale of surgical sutures

Alfresa Fine Chemical Corporation
Representative: Masahiko Kuretani, President and CEO
Head office: 1-10-1, Mukaihama, Akita, Akita Prefecture
Business domain: Manufacturing of active pharmaceutical ingredients

Investor Relations

https://www.alfresa.com/eng/ir/

Medical-Related Business

Overseas Business Development

https://www.alfresa.com/eng/about/business/overseas/

APOCREAT Corporation
Representative: Shizuhisa Kanemoto, President
Head office: 4-5-2, Higashi-Ikebukuro, Toshima-ku, Tokyo
Business domain: Dispensing pharmacy businessInformation System Business for the Alfresa Group
Alfresa System Corporation
Representative: Naruhiko Sano, President
Head office: 1-1, Kandanishikicho, Chiyoda-ku, Tokyo
Business domain: Operation, maintenance, and development of information
systems for the Alfresa Group

8

Alfresa Group Corporate Profile 2024–2025

Group Companies

https://www.alfresa.com/eng/about/group/

Alfresa Group Corporate Profile 2024–20259

Please see our corporate website for more details.

https://alfresa.com/eng/
Printed in Japan